Efficacy, Safety, and Quality of Life of Pegcetacoplan in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria Treated within the Phase 3 PEGASUS Trial
Acta Haematologica · 2024
DOI: 10.1159/000537696 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Acta Haematologica, 2024. Verfasst von Hisakazu Nishimori und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan. Hauptthemen laut MEDLINE: Hemoglobinuria, Paroxysmal, Quality of Life, Complement Inactivating Agents. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Pegcetacoplan, the first approved proximal complement C3 inhibitor, showed superiority to eculizumab in improving hemoglobin levels and clinical outcomes in the phase 3 PEGASUS study in patients with paroxysmal nocturnal hemoglobinuria (PNH) and inadequate response to eculizumab.
Methods
This analysis evaluates the efficacy and safety of pegcetacoplan for Japanese patients in PEGASUS, as they are known for different clinicopathologic features compared to non-Asian patients. Ten Japanese patients were enrolled to receive pegcetacoplan (n = 5) or eculizumab (n = 5) during the 16-week randomized controlled period. All patients received pegcetacoplan monotherapy during the open-label period until week 48.
Results
Treatment with pegcetacoplan improved hemoglobin with a mean change from baseline of 2.4 g/dL at week 16, which was sustained through 48 weeks. Pegcetacoplan-treated Japanese patients experienced sustained improvements in key secondary efficacy endpoints, including freedom from transfusion, lactate dehydrogenase level, reticulocyte count, and FACIT-Fatigue score. The safety profile was consistent with previously reported data from pegcetacoplan studies. No events of hemolysis, meningococcal infection, or thrombosis were reported in the Japanese population and all Japanese patients remained on treatment throughout the study.
Conclusion
These data suggest that Japanese patients with PNH can be effectively and safely managed with pegcetacoplan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
- Department of Hematology and Medical Oncology, Shinshu University School of Medicine, Matsumoto, Japan.
- Department of Hematology/Oncology, Wakayama Medical University Hospital, Wakayama, Japan.
- Department of Hematology and Oncology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
- Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan.
- Swedish Orphan Biovitrum AB, Stockholm, Sweden.
Zitieren
APA
Nishimori, H., Nakazawa, H., Tamura, S., Uchida, T., Usuki, K., Szamosi, J., de Latour, R. P., Röth, A., & Panse, J. (2024). Efficacy, Safety, and Quality of Life of Pegcetacoplan in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria Treated within the Phase 3 PEGASUS Trial. Acta Haematologica. https://doi.org/10.1159/000537696
Vancouver
Nishimori H, Nakazawa H, Tamura S, Uchida T, Usuki K, Szamosi J, et al. Efficacy, Safety, and Quality of Life of Pegcetacoplan in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria Treated within the Phase 3 PEGASUS Trial. Acta Haematologica. 2024. doi:10.1159/000537696
BibTeX
@article{Nishimori2024,
author = {Nishimori, Hisakazu and Nakazawa, Hideyuki and Tamura, Shinobu and Uchida, Toshiki and Usuki, Kensuke and Szamosi, Johan and de Latour, Régis Peffault and Röth, Alexander and Panse, Jens},
title = {Efficacy, Safety, and Quality of Life of Pegcetacoplan in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria Treated within the Phase 3 PEGASUS Trial},
journal = {Acta Haematologica},
year = {2024},
doi = {10.1159/000537696}
}
EUVIMED